ATE339436T1 - Expression von lipoproteinen - Google Patents

Expression von lipoproteinen

Info

Publication number
ATE339436T1
ATE339436T1 AT96918793T AT96918793T ATE339436T1 AT E339436 T1 ATE339436 T1 AT E339436T1 AT 96918793 T AT96918793 T AT 96918793T AT 96918793 T AT96918793 T AT 96918793T AT E339436 T1 ATE339436 T1 AT E339436T1
Authority
AT
Austria
Prior art keywords
protein
lipidated
disclosed
leader sequence
heterologous
Prior art date
Application number
AT96918793T
Other languages
English (en)
Inventor
Robert C Huebner
Lorne F Erdile
Donald J Warakomski
Robert S Becker
Maryanne B Gray
Derek L Pyle
Original Assignee
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Inc filed Critical Sanofi Pasteur Inc
Application granted granted Critical
Publication of ATE339436T1 publication Critical patent/ATE339436T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT96918793T 1995-06-07 1996-06-05 Expression von lipoproteinen ATE339436T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47578195A 1995-06-07 1995-06-07
US48637395A 1995-06-07 1995-06-07

Publications (1)

Publication Number Publication Date
ATE339436T1 true ATE339436T1 (de) 2006-10-15

Family

ID=27044930

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96918793T ATE339436T1 (de) 1995-06-07 1996-06-05 Expression von lipoproteinen

Country Status (13)

Country Link
EP (2) EP1741718A3 (de)
JP (1) JP4091112B2 (de)
AT (1) ATE339436T1 (de)
AU (1) AU721954B2 (de)
CA (2) CA2223300C (de)
DE (1) DE69636544T2 (de)
DK (1) DK0832093T3 (de)
ES (1) ES2271954T3 (de)
FI (1) FI974422A7 (de)
IL (1) IL118578A (de)
NO (2) NO324089B1 (de)
PT (1) PT832093E (de)
WO (1) WO1996040718A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
ZA964896B (en) * 1995-06-07 1997-01-08 Connaught Lab Expression of lipoproteins
EP1053329B1 (de) 1998-02-03 2009-10-07 Centers for Disease Control & Prevention Verfahren zur herstellung rekombinanter, lipid-modifizierter psaa proteine und deren verwendung
AU2003204215B2 (en) * 1998-02-03 2007-01-11 Aventis Pasteur Recombinant Lipidated PsaA Protein, Methods of Preparation and Use
NZ521531A (en) * 2000-02-28 2005-12-23 Chiron S Heterologous expression of neisserial proteins
ATE381575T1 (de) 2000-08-18 2008-01-15 Univ New York State Res Found Veränderte borrelia burgdorferi ospa
MY144532A (en) 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
WO2006045308A2 (en) 2004-10-25 2006-05-04 Statens Serum Institut Chlamydia trachomatis antigens for vaccine and diagnostic use
BRPI0612833A2 (pt) 2005-06-23 2010-11-30 Statens Seruminstitut composição imunogênica, vacina, composição farmacêutica, polipeptìdeo de fusão e uso das três primeiras
EP1981513B1 (de) 2006-01-19 2015-05-27 Mary Kay, Inc. Zusammensetzungen mit kakadupflaumenextrakt oder assaibeerenextrakt
US20090324638A1 (en) * 2006-06-12 2009-12-31 Biopeptides Corp. Live bacterial vaccine
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
PL2199303T3 (pl) 2008-12-12 2013-11-29 Euroimmun Medizinische Labordiagnostika Ag Polipeptydy i sposoby swoistego wykrywania przeciwciał u pacjentów z zakażeniem krętkami Borrelia
MX2011011186A (es) 2009-04-24 2012-02-13 Una vacuna antituberculosis tb para evitar la reactivacion.
US8048456B2 (en) 2009-08-28 2011-11-01 Mary Kay Inc. Skin care formulations
CN107913396B (zh) 2010-08-23 2022-03-08 惠氏有限责任公司 脑膜炎萘瑟氏菌rLP2086抗原的稳定制剂
AU2011300409B2 (en) 2010-09-10 2015-03-26 Wyeth Llc Non-lipidated variants of Neisseria meningitidis ORF2086 antigens
MY198910A (en) 2012-03-09 2023-10-02 Pfizer Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
WO2014136064A2 (en) 2013-03-08 2014-09-12 Pfizer Inc. Immunogenic fusion polypeptides
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
WO2016132294A1 (en) 2015-02-19 2016-08-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2021059181A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4624926A (en) * 1981-01-02 1986-11-25 The Research Foundation Of State University Of New York Novel cloning vehicles for polypeptide expression in microbial hosts
CA2032914A1 (en) * 1989-12-26 1991-06-27 Peter C.K. Lau Use of bacterial lipoprotein amino terminus in fusion plasmids for in vivo expression of lipid modified polypeptides
CA2084413A1 (en) * 1990-06-15 1991-12-16 Richard A. Flavell Compositions and methods for the prevention and diagnosis of lyme disease
FI933580A7 (fi) * 1991-02-15 1993-10-13 Uab Research Foundation Pneumokokkiproteiinin rakennegeeni
ES2194010T3 (es) * 1991-10-22 2003-11-16 Symbicom Ab Mejoras en el diagnostico y profilaxis de la borrelia burgdorferi.
WO1994014318A1 (en) * 1992-12-24 1994-07-07 Medimmune, Inc. Method of protection against streptococcus pneumoniae with transformed mycobacteria

Also Published As

Publication number Publication date
AU6134396A (en) 1996-12-30
IL118578A0 (en) 1996-10-16
EP0832093A1 (de) 1998-04-01
DE69636544T2 (de) 2007-06-06
EP1741718A3 (de) 2007-03-28
NO975619D0 (no) 1997-12-04
AU721954B2 (en) 2000-07-20
JPH11514841A (ja) 1999-12-21
EP0832093A4 (de) 2001-01-03
CA2223300C (en) 2010-07-27
NO20064621L (no) 1998-01-30
CA2223300A1 (en) 1996-12-19
FI974422A0 (fi) 1997-12-05
NO975619L (no) 1998-01-30
WO1996040718A1 (en) 1996-12-19
JP4091112B2 (ja) 2008-05-28
FI974422L (fi) 1998-02-04
FI974422A7 (fi) 1998-02-04
ES2271954T3 (es) 2007-04-16
DK0832093T3 (da) 2007-01-08
IL118578A (en) 2006-12-31
EP1741718A2 (de) 2007-01-10
EP0832093B1 (de) 2006-09-13
DE69636544D1 (de) 2006-10-26
PT832093E (pt) 2006-12-29
CA2704354A1 (en) 1996-12-19
NO324089B1 (no) 2007-08-13

Similar Documents

Publication Publication Date Title
DE69636544D1 (de) Expression von lipoproteinen
DK0397633T3 (da) Fibronectinbindende protein samt fremstilling deraf
DK0737207T3 (da) Inhibitorer for humant plasmin afledt af Kunitz-domæner
DE68917323D1 (de) Expressions-Vektor für Fusions-Proteine und Immunogen-Proteine.
NL1007028A1 (nl) Stabilisatorcombinatie.
IT8520226A0 (it) Sistema di controllo per motore commutato elettronicamente, sistema di motore commutato elettronicamente, macchina lavabiancheria e metodi per controllare la medesima.
AU4978496A (en) Encapsidated recombinant poliovirus nucleic acid
FI956075L (fi) Rekombinantti, ihon sarveiskerroksen kymotyptinen entsyymi (SCCE)
NO971875L (no) Cathepsin 02 protease
ATE263836T1 (de) Chimere proteine, welche borrelia polypeptide beinhalten, verwendungen dafür
IT1307309B1 (it) Peptidi stabilizzanti, polipeptidi ed anticorpi che li comprendono.
DK295188A (da) Fibronectinbindende protein og fremgangsmaade til fremstilling heraf
NL1006730A1 (nl) Stabilisatormengsels.
DE19681312T1 (de) Datenverbindungs-Steuerverfahren
HU9202074D0 (en) Collagen binding protein qnd method for producing it
FI960429L (fi) Menetelmä 1,4-butaanidiolin valmistamiseksi
SE9602822D0 (sv) New receptor
FI952738L (fi) Stabiiliproteiini, fosfolipidikoostumuksia ja menetelmiä
EP0612847A3 (de) Antimikrobielle Proteine.
FR2701953B1 (fr) Protéine de fusion multi-VIP et procédé de préparation de VIP recombinant.
NO892948D0 (no) Modifiserte proteiner.
NL1005505A1 (nl) Servobesturingsinrichting.
DE59005552D1 (de) Antriebsschlupfregelsystem.
ZA200007619B (en) New peptide fragments for protein purification.
SE9302856D0 (sv) Method and means for producing a plasmapeotein-binding protein

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0832093

Country of ref document: EP